Introduction
Thyroid cancer, the most common endocrine malignancy, has the fastest growing incidence of all cancers in the United States. Thyroid cancers in humans consist of an array of several different histological and biological types (Gillenwater and Weber, 1997) , but the majority of clinically important human thyroid cancers are of the differentiated papillary and follicular types. Although the patients with differentiated thyroid cancer have a good prognosis, recurrence could develop in 20-40% of patients, and with occurrence of distance metastases and extensive local invasion, the prognosis is much poorer. The molecular mechanisms underlying the initiation and progression of thyroid carcinoma are not fully understood, but it is generally believed that deregulation of cell growth and cell death are involved.
The creation of a mouse model of follicular thyroid cancer (TRb PV/PV mice) has provided a valuable tool to understand the molecular genetic events underlying thyroid carcinogenesis. The TRb PV/PV mouse was created by a targeted mutation of thyroid hormone-b receptor (TRbPV) via homologous recombination and the Cre-LoxP system (Kaneshige et al., 2000) . The thyroid hormone receptor-b mutant (denoted as PV) was identified in a patient (PV) with resistance to thyroid hormone (RTH) (Parrilla et al., 1991) . RTH is caused by mutations of the TRb gene and manifests symptoms as a result of decreased sensitivity to the thyroid hormone (T3) in target tissues (Olateju and Vanderpump, 2006) . PV has a C-insertion at codon 448 that produces a frameshift in the C-terminal 14 amino acids of TRb1. PV has completely lost T3 binding and exhibits potent dominant-negative activity (Meier et al., 1992) . As TRb PV/PV mice age, they spontaneously develop follicular thyroid carcinoma similar to human thyroid cancer with pathological progression from hyperplasia to vascular invasion, capsular invasion, anaplasia and eventually metastasis (Suzuki et al., 2002; Ying et al., 2003a, b) .
The steroid receptor activator-3 (SRC-3) is a member of p160 family that complexes with members of the steroid/thyroid hormone receptor superfamily to modulate their transcriptional activity (Liao et al., 2002; Lonard and O'Malley, 2005) . It was initially identified as an estrogen receptor coactivator amplified in breast and ovarian cancer (Anzick et al., 1997) . Subsequently, SRC-3 has been found overexpressed and/or amplified in other steroid hormone-sensitive tumors, such as prostate cancer and meningioma, as well as nonsteroid hormone-targeted tumors, such as pancreatic cancer, gastric cancer, colorectal carcinoma and hepatocellular carcinoma (Yan et al., 2006a) . Transgenic mice overexpressing SRC-3 display many types of malignancy in multiple tissues, such as mammary gland, pituitary, uterus, lung, liver and skin, through activation of insulin growth factor (IGF)/AKT signaling (Torres-Arzayus et al., 2004) .
Even though there have been some studies on the oncogenic functions of SRC-3 in other cancers (Liao et al., 2002) , the roles of SRC-3 in thyroid carcinogenesis are not known. To ascertain its effects on thyroid carcinogenesis, we crossed TRb PV/PV mice with SRC-3 null mice (Xu et al., 2000) and evaluated thyroid tumor development and progression in the offspring. We reported previously that deficiency in SRC-3 lessened the dysfunction of the pituitary-thyroid axis, indicating its important role in the modulation of RTH . In the present study, we further show that deficiency in SRC-3 delayed thyroid carcinogenesis of TRb PV/PV mice by increasing survival, reducing tumor growth and increasing apoptosis. Thus, SRC-3 is a tumor promoter in thyroid carcinogenesis in a mouse model of thyroid cancer.
Results

Deficiency of SRC-3 increases survival of TRb
PV/PV mice We have previously shown that TRb PV/PV mice have high mortality caused by follicular thyroid carcinoma. To evaluate the effect of SRC-3 on thyroid carcinogenesis, we first compared the survival curves of TRb PV/PV mice with or without ablation of the SRC-3 alleles (Figure 1a) . Analysis of the data shows that the 50% survival ages for TRb PV/PV SRC-3 À/À and TRb PV/PV SRC-3 þ / þ mice were 280733 and 22678 days, respectively. These data indicate that TRb PV/PV SRC-3 þ / þ mice died at a significantly younger age than TRb PV/PV SRC-3 À/À mice did (Po0.001). When the survival curves were analysed separately for males and females (Supplemental Figure A) , similar significant increases in survival of TRb PV/PV mice by SRC-3 deficiency were observed.
Deficiency of SRC-3 inhibits thyroid growth of TRb PV/PV mice The above results prompted us to evaluate the effect of SRC-3 deficiency on thyroid growth of TRb PV/PV mice. Figure 1b compares the ratios of thyroid weight versus body weight of age-matched TRb PV/PV mice with or without SRC-3 as they aged. Consistent with our previous studies (Suzuki et al., 2002; Ying et al., 2003b; Kato et al., 2004 Kato et al., , 2006 , thyroid growth of TRb mice at age 3-5, 6-8, 9-11 and 12-14 months, respectively. These results show that lack of SRC-3 significantly inhibited thyroid growth in TRb PV/PV mice as they aged. No gender differences in the inhibitory effect of thyroid growth by SRC-3 deficiency were noted (Supplemental Figure B) .
Deficiency of SRC-3 delays thyroid tumor progression of TRb PV/PV mice To understand whether lack of SRC-3 affected thyroid tumor progression, we carried out histopathological analysis and compared the percentage occurrence of capsular and vascular invasion and metastasis in TRb PV/PV mice with or without SRC-3 (Figure 2 ). Capsular and vascular invasion and metastasis are the main diagnostic criteria to distinguish between the benign and malignant lesions of human thyroid. While more than 90% of TRb PV/PV mice developed capsular invasion between 6 and 14 months (closed bars, Figure 2a ), a significant 50% reduction in the occurrence of capsular invasion was observed in TRb PV/PV mice deficient in SRC-3 (open bars, Figure 2a ). While more than 55% of TRb PV/PV mice developed vascular invasion between 6 and 14 months (closed bars, Figure 2b ), no vascular invasion was detected for TRb PV/PV mice deficient in SRC-3 until the age of 12-14 months with a significant 80% reduction in the occurrence as compared to TRb Figure 2b ). Similarly, while 10, 45 and 65% of TRb PV/PV SRC-3 þ / þ mice developed lung metastasis at the ages of 6-8, 9-11 and 12-14 months, respectively, no metastasis occurred for TRb PV/PV SRC-3 À/À mice at the age Lack of SRC-3 inhibits thyroid growth via inhibiting cell cycle progression SRC-3 has been reported to play an important role in cell cycle progression (Louie et al., 2004 (Louie et al., , 2006 . To address the question of how SRC-3 ablation reduced thyroid growth (Figure 1b) , we compared the cell cycle distribution in the thyroid tumors of TRb PV/PV SRC-3 À/À mice with age-matched TRb PV/PV SRC-3 þ / þ mice. As shown in Figure 3a , a significant increase in the G 1 /G 0 (compare bar 2 with 1) phase accompanied by a decrease in the G 2 /M phase (compare bar 6 with 5) was detected in TRb PV/PV SRC-3 À/À mice as compared with TRb PV/ PV SRC-3 þ / þ mice, indicating that the lack of SRC-3 delayed the cell cycle progression of thyroid tumor cells. To ascertain whether the inhibition of cell cycle progression was mediated by SRC-3, we prepared thyroid tumor cells from TRb PV/PV mice and knocked down specifically the expression of SRC-3 by means of an siRNA approach (Figures 3c and d) . Indeed, in thyroid tumor cells in which the expression of SRC-3 was knocked down, there was a similar increase in the G 1 /G 0 phase (Figure 3b) and decrease in the G 2 /M phase (Figures 3a and b) . Consistent with observations reported by others, these in vivo and in vitro findings suggested that the delay in cell cycle progression is mediated by the lack of SRC-3 and is accounted for, at least in part, the reduced proliferation of thyroid tumor cells in TRb PV/PV SRC-3 À/À mice. To understand further the mechanisms by which the lack of SRC-3 delayed the entry of tumor cells from the G 1 /G 0 phase into the subsequent cell cycles, we analysed the expression of key cell cycle regulators critical for the G 1 /S-phase transition. Figure 3c shows that the mRNA expression of E2F1, cyclin-dependent kinase (Cdk2), Cdc6 (DNA replication regulator) and Cdc25a phosphatase (S-phase entry regulator) was reduced in thyroid tumor cells deficient in SRC-3. Consistent with findings by others (Louie et al., 2004 (Louie et al., , 2006 , the reduced expression of these positive regulators in the G 1 /S-phase transition by the SRC-3 knockdown contributed to the G 1 /G 0 arrest induced by SRC-3 deficiency (Figure 3b ).
In addition, knockdown of SRC-3 expression also significantly increased the protein levels of negative regulators such as Rb and p27 at the G 1 /S transition ( Figure 3d ). It is important to note that there were no changes in the hyperphosphorylated Rb that acts to release the E2F1 to drive the expression of the S-phase transcription factors, further contribute to arrest the cells in the G 1 /G 0 phase. However, the protein levels of p21 were moderately reduced by the knockdown of SRC-3 expression. Taken together, these data further support the notion that SRC-3 could delay cell cycle progression by mediating cell cycle gene expression.
Deficiency of SRC-3 induces apoptosis through regulating Bcl-2 and caspase-3 The decreased tumor growth (Figure 1b ) could also be due to increased apoptosis in TRb PV/PV mice deficient in SRC-3. This proposal is based on the observation that SRC-3 acts to increase prostate cancer cell survival by decreasing apoptosis (Zhou et al., 2005) . Using immunohistochemical analysis, we therefore examined whether apoptotic activity was increased in thyroid tumors of TRb PV/PV SRC-3 À/À mice by first examining the protein abundance of the cleaved active caspase-3. Compared with the staining intensity of the cleaved active caspase-3 in tumor cells of TRb PV/PV SRC-3 þ / þ (Figure 4Aa ), the protein abundance of cleaved active caspase-3 was increased in tumor cells of TRb PV/PV SRC-3 À/À mice (arrows in Figure 4Ab ). Cells positively labeled with cleaved active caspase-3 were quantified to indicate a 9. Oncogenic activity of SRC-3 in thyroid carcinogenesis H Ying et al indicate an increase in the apoptotic activity of tumor cells deficient in SRC-3, thereby further contributing to reduced tumor growth. To understand the mechanism underlying the increased apoptotic activity in tumor cells deficient in SRC-3, we evaluated the expression of the proapoptotic gene, caspase-3 as well as the antiapoptotic gene, Bcl-2, in the thyroid of TRb PV/PV mice with or without SRC-3 by real-time reverse transcription-PCR ( Figure 4B ) and western blot analysis ( Figure 4C ). These two genes have been shown to be negatively or positively regulated by SRC-3 (Zhou et al., 2005; Yan et al., 2006b) , respectively. Analysis by real-time RT-PCR indicates that the mRNA level of Bcl-2 was repressed by 31% in tumor cells deficient in SRC-3 (Figure 4Ba , compare bar 2 with 1). In contrast, caspase-3 mRNA expression was increased 1.9-fold in tumor cells deficient in SRC-3 (Figure 4Bb , compare bar 2 with 1). The protein abundance of Bcl-2 and caspase-3 was also evaluated by western blot analysis ( Figure 4C ). Consistent with the alterations at the mRNA level, the protein abundance of Bcl-2 was decreased (compare lanes 6-10 with lanes 1-5, upper panel, Figure 4Ca ), whereas that of caspase-3 (lanes 6-10 versus 1-5; middle panel, Figure 4Ca ) was increased in the thyroid of TRb PV/PV mice deficient in SRC-3. The intensities in the western blots were quantified, normalized to the loading control of proteindisulfide isomerase (PDI, lower panel, Figure 4Ca ) and graphed ( Figure 4Cb ). The quantitative analysis shows that Bcl-2 protein abundance was significantly decreased 41% (left panel, Figure 4Cb ), whereas the caspase-3 protein level was significantly increased by 3.3-fold (right panel Figure 4Cb ) in the thyroid of TRb PV/PV SRC-3
mice as compared with TRb PV/PV SRC-3 þ / þ mice. To further confirm that the changes shown above were mediated via SRC-3, we knocked down specifically SRC-3 expression in thyroid tumor cells derived from TRb PV/PV SRC-3 þ / þ mice using an siRNA approach. Figure 4Da shows that SRC-3 protein levels were reduced by knockdown using siRNA treatment (compare lane 2 with 1). Concomitant with reduced SRC-3 expression, Bcl-2 protein abundance was decreased ( Figure 4Db ) and caspase-3 was increased ( Figure  4Dc ). Panel d (Figure 4D) shows the corresponding loading controls using a-tubulin. These results suggest that deficiency in SRC-3 led to a reduction of the antiapoptotic Bcl-2 and an induction of the apoptotic executioner, caspase-3, resulting in increased apoptotic activity to contribute to decreased thyroid tumor growth of TRb PV/PV SRC-3 À/À mice. SRC-3 À/À mice as compared with that in TRb PV/PV SRC-3 þ / þ mice (compare bar 2 with 1), indicating that SRC-3 deficiency could suppress neovascularization through downregulation of the Vegf-A expression. The expression of another growth factor, fibroblast growth factor 2, which also plays a role in angiogenesis, was not changed by SRC-3 deficiency (data not shown).
The findings that lack of SRC-3 delayed the metastatic spread to the lung of TRb PV/PV mice also prompted 
SRC-3
À/À mice moved at a significantly slower rate than those derived from TRb PV/PV SRC-3 þ / þ mice. These results indicate that the lack of SRC-3 decreased cell motility and cell migration, resulting in decreasing metastasis from primary thyroid tumor lesions to distant organs such as the lung. Vegf-A is also known to promote cell migration. Thus, the reduced expression of Vegf-A due to SRC-3 deficiency could account, at least in part, for the reduced cell motility and migration.
Discussion
The availability of a mouse model of follicular thyroid carcinoma has allowed us to uncover cellular factors that could contribute to carcinogenesis in vivo. With use of this mouse model, the present study identified a receptor coactivator, SRC-3, that participates in the oncogenic process of tumor development. Consistent with reports of diverse roles for SRC-3 in cellular processes, this study found that SRC-3 acted at multiple pathways to affect the thyroid carcinogenesis in vivo. The lack of SRC-3 in TRb PV/PV mice resulted in reduced tumor cell proliferation by prolonging the G 1 /G 0 phase via control of the expression and activities of cell cycle key regulators. The lack of SRC-3 in TRb PV/PV mice led to increased apoptotic activity via increased expression of caspase-3 and decreased expression of antiapoptotic Bcl-2. Furthermore, the decreased expression of Vegf-A in TRb PV/PV mice deficient in SRC-3 could partly account for the decreased cell motility and migration. Taken together, these findings suggest that SRC-3 functions as a tumor promoter in thyroid carcinogenesis via its effects on multiple signaling pathways.
At present, how the deficiency of SRC-3 led to the alterations of the gene expression in TRb PV/PV mice is not clear. However, it has become increasingly apparent that the functions of SRC-3 are not limited to acting as a transcription coactivator of liganded nuclear receptors (Torres-Arzayus et al., 2004; Zhou et al., 2005; Yan et al., 2006b) . For example, it was shown that prostate cancer cell proliferation requires SRC-3 for transitioning cells from the G 1 /G 0 phase to the S phase (Zhou et al., 2005) . However, this SRC-3-dependent cell cycle progression occurred in both the presence and the absence of androgens. Furthermore, SRC-3 is also required for prostate cancer cell survival in that when its expression is decreased, the expression of Bcl-2 is decreased and apoptosis increased. These changes were postulated to involve the AKT signaling and/or the nuclear factor-kB pathway (Wu et al., 2002; Zhou et al., 2005) . In line with these observations, we have previously shown that SRC-3 modulates the growth of thyroid via the IGF-1-phosphatidylinositol 3-kinase-AKT-mTOR pathway, independent of thyroid hormone . Thus, the present study further supports the idea that the oncogenic actions of SCR-3 encompass more than acting as a coactivator of nuclear receptor transcription. Clearly, future work is needed to elucidate how SRC-3 integrates its diverse cellular actions in carcinogenesis.
It is important to note that the present study shows that SRC-3 was also required for thyroid tumor cell proliferation and survival. The SRC-mediated alterations in the expression profiles of key regulators in the G 1 /S-phase transition and apoptotic process in the thyroid tumors were similar to those of prostate cancer cells (Zhou et al., 2005) . The similar dependency of SRC-3 for cancer cell growth and survival in two different cancer organs (that is, thyroid and prostate) suggests that the role of SRC-3 in cancer biology could be more critical than previously envisioned. The in vivo findings that lack of SRC-3 delayed thyroid tumor progression and reduced distant metastasis in TRb PV/PV mice suggests that SRC-3 per se is a potential therapeutic target. The therapeutic opportunities are increased by the demonstration that oncogenic actions of SRC-3 involve signaling pathways mediated by phosphorylation cascades of membrane receptors and effectors Yan et al., 2006a) as kinase inhibitors are increasingly being developed and expanded. The availability of the TRb PV/PV mouse model of thyroid cancer will allow for testing of these possibilities.
Materials and methods
Mouse strains
TRbPV mice have a mixed background of 129Sv X C57BL strains and SRC-3 null mice have a similar mixed background of 129Sv X C57. Mice with mixed genders were used in the analysis.
Histopathological analysis
For thyroids, morphological evidence of hyperplasia, capsular invasion, vascular invasion and anaplasia were routinely counted in the hematoxylin and eosin-stained sections as described (Kato et al, 2006 ). An interpretation of capsular invasion required the presence of a clear collection of thyroid epithelial cells external to a clearly discernable capsule, usually Oncogenic activity of SRC-3 in thyroid carcinogenesis H Ying et al in a collagenous stroma, and vascular invasion required the presence of a cluster of epithelial cells within the confines of an endothelial-lined vascular channel. Similarly, examination of lung metastases was performed on single sections from each animal and any clear example of thyroid epithelial cells present in the lung was sufficient to interpret this as metastatic, although most cases with metastases had multiple metastatic sites within the lung parenchyma.
Transfection, cell cycle analysis and cell motility assay Thyroid tumor cells derived from TRb PV/PV thyroid were cultured similarly as described (Kato et al., 2006) . SRC-3-specific siRNA (80 mM, Dharmacon, Lafayette, CO, USA) was transfected into cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Cell cycle analysis and cell motility assay were carried out similarly as described (Kim et al., 2007) . Preparation of primary thyroid cells from fresh tissues was described before (Ying et al., 2003b) .
Quantitative real time RT-PCR
The QuantiTect SYBR green RT-PCR kit (Qiagen) was used as per the manufacturer's instructions. Primers for GAPDH , Vegfa (Kim et al., 2007) , and caspase-3 (Kato et al., 2006) have been described previously. The primer sequences of other genes were provided as Supplemental data.
Western blot and immunohistochemistry
Primary antibodies for cyclin D1, Rb, p21, p27, caspase-3, PDI and a-tubulin were described previously (Furumoto et al., 2005; Kato et al., 2006) . Anti-SRC-3 antibodies were a gift from Ray-chang Wu (Baylor College of Medicine). Cleaved caspase-3 was detected via immunohistochemistry, and the morphometric quantitation was carried out as described before (Kato et al., 2006) . Band intensities were evaluated using NIH IMAGE Software (ImageJ 1.34s; http://rsb.info.nih.gov/ij).
Statistical analysis
All statistical analysis was carried out using StatView 5.0. (SAS Institute Inc.). Kaplan-Meier analysis and log-rank (Mantel-Cox) test were used for survival analysis; a two-way contingency table was used for histological evaluation; analysis of variance was used for thyroid weight analysis and Student's t-test was used for analysis of mRNA and protein expression, cell cycle distribution and motility.
